CompletedNCT03586427
Zelquistinel for Major Depression
About this title
Read the official source — NCT03586427Researchers compared AGN-241751 and placebo to find out how the approaches affected depression symptoms in adults with depression.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared AGN-241751 and placebo to find out how the approaches affected depression symptoms in adults with depression.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Fayetteville and 24 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: June 13, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 251
- Sponsor
- Syndeio Biosciences, Inc
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03586427
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of AGN-241751 in Adult Participants With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Fayetteville · Cerritos · Encino
20 more locations
- Newport Beach
- Oakland
- Oceanside
- Torrance
- Wildomar
- Atlanta
- Lincolnwood
- Boston
- Berlin
- Cherry Hill
- Cedarhurst
- Jamaica
- New York
- Rochester
- North Canton
- Oklahoma City
- Memphis
- Austin
- Dallas
- Bellevue
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared AGN-241751 and placebo to find out how the approaches affected depression symptoms in adults with depression.
Who is behind this study?
The study sponsor is Syndeio Biosciences, Inc.
Did this study involve medication?
Yes. The study involved medication, including AGN-241751 and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
